Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6

Yes a very good quarter with signifiicant value created that wasn't there when AGN floated such as "Positive efficacy results from a preclinical study of ARG-007 in a late pre-term animal model of hypoxicischaemic encephalopathy (HIE). " This is a huge and important new application.

Many more applications to come IMO.

The Phase 1 trial start is delayed but we have learnt so much more more about ARG 007 in the meantime. The announcement on the 13th Jan of the appointment of Dr Meghan Thomas is a plus and the start date of 1st April told us the trial wasn't starting this quarter.

AGN has there hands on a potential blockbusting drug and as a shareholder I want all the ducks lined up properly before the Phase 1 trial begins.

Plenty of important newsflow to come in the meantime.